Search

Your search keyword '"Prevots, D. Rebecca"' showing total 459 results
Start Over Author "Prevots, D. Rebecca"
459 results on '"Prevots, D. Rebecca"'

52. Interruption of Measles Transmission in Brazil, 2000-2001

Author

Prevots, D. Rebecca, Parise, M. Salet, Segatto, Teresa Cristina V., Siqueira, Marilda Mendonça, dos Santos, Elizabeth D., Ganter, Bernardus, Perreira, Maria Carolina C. Q., Domingues, Carla A., Lanzieri, Tatiana, and da Silva, Jarbas Barbosa

Published
2003

57. Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design

Author

Gross, Jane E., primary, Caceres, Silvia, additional, Poch, Katie, additional, Hasan, Nabeeh A., additional, Davidson, Rebecca M., additional, Epperson, L. Elaine, additional, Lipner, Ettie, additional, Vang, Charmie, additional, Honda, Jennifer R., additional, Strand, Matthew, additional, Strong, Michael, additional, Saiman, Lisa, additional, Prevots, D. Rebecca, additional, Olivier, Kenneth N., additional, and Nick, Jerry A., additional

Published
2021
Full Text
View/download PDF

60. 1408. Population-based Nontuberculous Mycobacteria Surveillance in Four Emerging Infections Program Sites, October 2019–March 2020

Author

Jackson, Kelly A, primary, Barter, Devra, additional, Czaja, Christopher A, additional, Johnston, Helen, additional, Lynfield, Ruth, additional, Vagnone, Paula Snippes, additional, Tourdot, Laura, additional, Spina, Nancy, additional, Dumyati, Ghinwa, additional, Peters, Shantel, additional, Escutia, Gabriela, additional, Pierce, Rebecca, additional, Henkle, Emily, additional, Prevots, D Rebecca, additional, Salfinger, Max, additional, Winthrop, Kevin L, additional, Toney, Nadege Charles, additional, Magill, Shelley, additional, and Grigg, Cheri, additional

Published
2021
Full Text
View/download PDF

61. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011

Author

de Mello, Karla Gripp Couto, Mello, Fernanda C. Queiroz, Borga, Liamar, Rolla, Valeria, Duarte, Rafael S., Sampaio, Elizabeth P., Holland, Steven M., Prevots, D. Rebecca, and Dalcolmo, Margareth P.

Subjects
Diagnosis, Care and treatment, Research, Risk factors, Mycobacterium infections -- Risk factors -- Diagnosis -- Research -- Care and treatment, Mycobacterial infections -- Risk factors -- Diagnosis -- Research -- Care and treatment
Abstract

Pulmonary disease caused by nontuberculous mycobacteria (PNTM) frequently causes sickness and death. These bacteria are found in water sources and soil and are particularly concentrated in biofilms (1,2). Certain clinical [...]

Published
2013
Full Text
View/download PDF

63. Hospitalizations associated with disseminated coccidioidomycosis, Arizona and California, USA

Author

Seitz, Amy E., Prevots, D. Rebecca, and Holland, Steven M.

Subjects
Health aspects, HIV infections -- Health aspects, African Americans -- Health aspects, Medical research -- Health aspects, Infection -- Health aspects, Coccidioidomycosis -- Health aspects, Medicine, Experimental -- Health aspects, HIV infection -- Health aspects
Abstract

Coccidioidomycosis is a fungal infection caused by inhalation of Coccidioides immitis or C. posadasii spores (1,2). Most ([approximately equal to] 60%) persons infected with Coccidioides spp. are asymptomatic (3), but [...]

Published
2012
Full Text
View/download PDF

67. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005

Author

Billinger, Megan E., Olivier, Kenneth N., Viboud, Cecile, de Oca, Ruben Montes, Steiner, Claudia, Holland, Steven M., and Prevots, D. Rebecca

Subjects
Diseases, Development and progression, Hospital patients, Lung diseases -- Development and progression
Abstract

Clinic- and laboratory-based studies since the 1980s have shown an increased prevalence of persons with nontuberculous mycobacterial (NTM) pulmonary disease (1,2) with a predominance of women >60 years of age [...]

Published
2009
Full Text
View/download PDF

70. Vaccine policy changes and epidemiology of poliomyelitis in the United States

Author

Alexander, Lorraine Nino, Santibanez, Tammy A., Kew, Olen M., Strebel, Peter M., Wharton, Melinda, Seward, Jane F., Pallansch, Mark A., Prevots, D. Rebecca, Cono, Joanne, Orenstein, Walter A., and Sutter, Roland W.

Subjects
Poliomyelitis vaccine -- Dosage and administration, Poliomyelitis -- Development and progression, Poliomyelitis -- Prevention
Abstract

The epidemiology of paralytic poliomyelitis reviewed, and the association between the vaccine schedule changes and vaccine-associated paralytic poliomyelitis (VAPP) in the United States is documented. The change in polio vaccination policy from oral poliovirus vaccine (OPV) to exclusive use of inactivated poliovirus vaccine (IPV) was successful implemented, which led to the elimination of VAPP in the United States.

Published
2004

72. Parental attitudes toward multiple poliovirus injections following a provider recommendation. (Feature Article)

Author

Kolasa, Maureen S., Bisgard, Kristine M., Prevots, D. Rebecca, Desai, Shalini N., and Dibling, Karen

Subjects
Poliomyelitis vaccine -- Adverse and side effects, Immunization of children -- Health aspects, Physician and patient -- Communication
Abstract

The routine use of the oral poliovirus vaccine (OPV) resulted in an average of eight to nine cases of vaccine-associated paralytic polio (VAPP) annually in the US between 1980 and […]

Published
2001

78. Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research

Author

Daniel-Wayman, Shelby, primary, Abate, Getahun, additional, Barber, Daniel L., additional, Bermudez, Luiz E., additional, Coler, Rhea N., additional, Cynamon, Michael H., additional, Daley, Charles L., additional, Davidson, Rebecca M., additional, Dick, Thomas, additional, Floto, R. Andres, additional, Henkle, Emily, additional, Holland, Steven M., additional, Jackson, Mary, additional, Lee, Richard E., additional, Nuermberger, Eric L., additional, Olivier, Kenneth N., additional, Ordway, Diane J., additional, Prevots, D. Rebecca, additional, Sacchettini, James C., additional, Salfinger, Max, additional, Sassetti, Christopher M., additional, Sizemore, Christine F., additional, Winthrop, Kevin L., additional, and Zelazny, Adrian M., additional

Published
2019
Full Text
View/download PDF

81. Invasive Candidiasis Species Distribution and Trends, United States, 2009-2017.

Author

Ricotta, Emily E, Lai, Yi Ling, Babiker, Ahmed, Strich, Jeffrey R, Kadri, Sameer S, Lionakis, Michail S, Prevots, D Rebecca, and Adjemian, Jennifer

Subjects
CANDIDEMIA, INVASIVE candidiasis, SPECIES distribution, HEALTH facilities, MEDICAL record databases, INTRODUCED species, GENERALIZED estimating equations, ANTIFUNGAL agents, CANDIDA, DISEASE incidence, ANIMALS, MICROBIAL sensitivity tests
Abstract

Background: Invasive candidiasis (IC) is a growing concern among US healthcare facilities. A large-scale study evaluating incidence and trends of IC in the United States by species and body site is needed to understand the distribution of infection.Methods: An electronic medical record database was used to calculate incidence and trends of IC in the United States by species and infection site from 2009 through 2017. Hospital incidence was calculated using total unique inpatient hospitalizations in hospitals reporting at least 1 Candida case as the denominator. IC incidence trends were assessed using generalized estimating equations with exchangeable correlation structure to fit Poisson regression models, controlling for changes in hospital characteristics and case mix over time.Results: Candida albicans remains the leading cause of IC in the United States, followed by Candida glabrata. The overall incidence of IC was 90/100 000 patients, which did not change significantly over time. There were no changes in incidence among C. albicans, C. glabrata, C. parapsilosis, or C. tropicalis; the incidence of other Candida spp. as a whole increased 7.2% annually. While there was no change in candidemia 2009-2017, abdominal and nonabdominal sterile site IC increased significantly.Conclusions: Nonbloodstream IC is increasing in the United States. Understanding the epidemiology of IC should facilitate improved management of infected patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

82. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991

Author

Prevots, D. Rebecca, Sutter, Roland W., Strebel, Peter M., Weibel, Robert E., and Cochi, Stephen L.

Subjects
Poliomyelitis vaccine -- Adverse and side effects, Poliomyelitis -- Risk factors, Health
Abstract

Background: Although the risk of vaccine-associated paralytic poliomyelitis (VAPP) has remained relatively constant during the past 30 years, estimates of VAPP depend largely on the completeness of reporting to the existing passive surveillance system. The National Vaccine Injury Compensation Program constitutes an alternative system for reporting VAPP, and data available from this system permitted us to evaluate the completeness of the national poliomyelitis surveillance system. Methods: We compared cases of paralytic poliomyelitis reported to the national surveillance system (maintained by the Centers for Disease Control and Prevention, Atlanta, Ga) with cases recommended for compensation by the National Vaccine Injury Compensation Program, Rockville, Md, and we calculated the observed completeness of reporting to the national system for 1980 through 1991. A capture-recapture method was also used to estimate completeness of reporting, ie, to account for cases potentially missed by both systems. In addition, we reviewed the epidemiology and updated the risk of VAPP based on the most current information on cases of VAPP. Results: From 1980 through 1991, 105 cases of paralytic poliomyelitis were identified by the Centers for Disease Control and Prevention and National Vaccine Injury Compensation Program systems, 98 (93%) of which were VAPP (average, 8.2 cases per year). The observed completeness of reporting to the Centers for Disease Control and Prevention was 94%, and the estimated completeness of reporting (capture-recapture method) was 81%. The over all risk of VAPP was one caseper 2.5 million doses of oral poliovirus vaccine distributed. In the sensitivity analysis, the risk estimates of VAPP remained relatively stable throughout a wide range of assumptions regarding underreporting and specificity of the case definition for paralytic poliomyelitis. Conclusion: The risk of VAPP remains virtually unchanged from previous estimates despite the inclusion of previously unidentified VAPP cases. Despite the potential for both underreporting and misclassification of cases, our risk estimates were relatively insensitive to either of these biases. Since both of these biases were in opposite directions, and both probably occurred with low frequency, the risk estimates provided in this report appear valid and approximate the 'true' risk of VAPP in the United States. (Arch Pediatr Adolesc Med. 1994;148:479-485), The risk of vaccine-associated paralytic poliomyelitis (VAPP) appears to be at a level consistent with previous estimates and it appears that VAPP cases are relatively well-reported. Paralytic poliomyelitis damages motor neurons, resulting in a paralysis of the limbs, and can be acquired through reactions to the oral polio vaccine. Records from the Centers for Disease Control and Prevention (CDC) and the National Vaccine Injury Compensation Program were reviewed for 1980 through 1991. One-hundred and five cases were reported for the time period, an average of 8.7 cases per year. The CDC had records of 94% of the known instances of VAPP and a capture-recapture analysis suggests that 81% of all cases were actually reported. Based on reported cases, the risk of VAPP was one case per 2.5 million doses of distributed oral poliovirus vaccine. This number did not change dramatically when assumptions regarding underreporting were factored in.

Published
1994

84. Mycobacterial Testing Trends, United States, 2009-20151.

Author

Dean, Samantha G., Ricotta, Emily E., Fintzi, Jonathan, Yi Ling Lai, Kadri, Sameer S., Olivier, Kenneth N., Zelazny, Adrian, Prevots, D. Rebecca, and Lai, Yi Ling

Subjects
OLDER women, HEALTH facilities, MYCOBACTERIA
Abstract

We studied 31 US healthcare facilities to characterize trends in mycobacterial testing. During 2009-2015, testing for acid-fast bacilli increased 3.2% annually, and prevalence of pathogenic nontuberculous mycobacteria increased 4.5% annually. These increases were highest for subpopulations at high risk of infection, including older women, Asians, and patients with concurrent conditions. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

92. Missing diagnoses of congenital cytomegalovirus infection in electronic health records for infants with laboratory-confirmed infection.

Author

Campione, Alexandra, Lanzieri, Tatiana M., Ricotta, Emily, Grosse, Scott D., Kadri, Sameer S., Nussenblatt, Veronique, and Prevots, D. Rebecca

Subjects
CYTOMEGALOVIRUS diseases, ELECTRONIC health records, CONGENITAL disorders, SALIVA, INFANT health, DIAGNOSIS, SENSORINEURAL hearing loss, FLUORESCENT antibody technique
Abstract

Congenital cytomegalovirus (CMV) is a leading cause of non-genetic sensorineural hearing loss and neurodevelopmental disabilities among US children. Studies using administrative healthcare databases have identified infants with congenital CMV using diagnostic codes from the International Classification of Diseases, Ninth and Tenth Revision, Clinical Modification. Using Cerner Health Facts deidentified electronic health records, we assessed the sensitivity of CMV diagnostic codes among infants with laboratory confirmed congenital CMV infection (i.e. a positive CMV laboratory test – polymerase chain reaction, direct fluorescent antibody, or culture from urine, saliva, respiratory secretion or blood samples, or IgM serology – within 21 days of life). During 2010–2017, 668 congenital CMV cases were identified among 7,517,207 infants with encounters within 21 days of life, or 0.89 cases per 10,000 infants. The sensitivity of CMV diagnostic codes assigned within 21 and 90 days of life was 10.3% (95% CI: 8.2–12.9) and 11.1% (95% CI: 8.9–13.7), respectively. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

93. Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil

Author

Couto de Mello, Karla Gripp, Queiroz Mello, Fernanda C., Borga, Liamar, Rolla, Valeria, Duarte, Rafael S., Sampaio, Elizabeth P., Holland, Steven M., Prevots, D. Rebecca, and Dalcolmo, Margareth P.

Subjects
Adult, Lung Diseases, Male, Microbiology (medical), nontuberculous mycobacteria, mycobacteria, atypical, medicine.medical_specialty, Tuberculosis, Epidemiology, mycobacteria, Prevalence, Mycobacterium Infections, Nontuberculous, lcsh:Medicine, Disease, Article, lcsh:Infectious and parasitic diseases, Young Adult, Acquired immunodeficiency syndrome (AIDS), Internal medicine, Diabetes mellitus, CME, Humans, Medicine, lcsh:RC109-216, bacteria, Aged, Aged, 80 and over, Mycobacterium kansasii, Bronchiectasis, biology, business.industry, Research, lcsh:R, Hepatitis C, Middle Aged, Mycobacterium avium Complex, biology.organism_classification, medicine.disease, bacterial infections and mycoses, tuberculosis and other mycobacteria, Anti-Bacterial Agents, Treatment Outcome, Infectious Diseases, atypical, Immunology, Female, business, Brazil
Abstract

To identify clinical and therapeutic features of pulmonary nontuberculous mycobacterial (PNTM) disease, we conducted a retrospective analysis of patients referred to the Brazilian reference center, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, who received a diagnosis of PNTM during 1993–2011 with at least 1 respiratory culture positive for NTM. Associated conditions included bronchiectasis (21.8%), chronic obstructive pulmonary disease (20.7%), cardiovascular disease (15.5%), AIDS (9.8%), diabetes (9.8%), and hepatitis C (4.6%).Two patients had Hansen disease; 1 had Marfan syndrome. Four mycobacterial species comprised 85.6% of NTM infections: Mycobacterium kansasii, 59 cases (33.9%); M. avium complex, 53 (30.4%); M. abscessus, 23 (13.2%); and M. fortuitum, 14 (8.0%). A total of 42 (24.1%) cases were associated with rapidly growing mycobacteria. In countries with a high prevalence of tuberculosis, PNTM is likely misdiagnosed as tuberculosis, thus showing the need for improved capacity to diagnose mycobacterial disease as well as greater awareness of PNTM disease prevalence.

Published
2013

96. Hemoglobin variants shape the distribution of malaria parasites in human populations and their transmission potential

Author

Gonçalves, Bronner P., primary, Sagara, Issaka, additional, Coulibaly, Mamadou, additional, Wu, Yimin, additional, Assadou, Mahamadoun H., additional, Guindo, Agnes, additional, Ellis, Ruth D., additional, Diakite, Mahamadou, additional, Gabriel, Erin, additional, Prevots, D. Rebecca, additional, Doumbo, Ogobara K., additional, and Duffy, Patrick E., additional

Published
2017
Full Text
View/download PDF

100. Neonatal tetanus(*)

Author

Prevots, D. Rebecca

Subjects
Prevention, Analysis, Research, Tetanus -- Prevention -- Research, Cross-sectional studies -- Analysis -- Research, World health -- Research -- Analysis, Observational studies -- Analysis -- Research
Abstract

1. Brief description of the condition/disease Neonatal tetanus (NT) results from Clostridium tetani infection of the umbilical stump at or following delivery of a child born to a mother without [...]

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results